Silodosin - Kissei Pharmaceutical
Alternative Names: KAD 3213; KMD-3213; KSO-0400; Rapaflo; Silodyx; Thrupas; Urief; Urief OD; UrorecLatest Information Update: 05 Nov 2023
At a glance
- Originator Kissei Pharmaceutical
- Developer AbbVie; Actavis; Almirall S.A.; Daiichi Sankyo Company; Eisai Co Ltd; JW Pharmaceutical; Kissei Pharmaceutical; Mayne Pharma Group; Pharmaplan; Recordati; Synmosa Biopharma; Zambon France
- Class Benzamides; Indoles; Muscle relaxants; Small molecules; Urologics
- Mechanism of Action Alpha-1a adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Benign prostatic hyperplasia
- Phase II Urinary calculi
- No development reported Nocturia; Prostatitis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 06 Aug 2019 Launched for Benign prostatic hyperplasia in Malaysia before August 2019 (PO) (Kissei Pharmaceutical pipeline August 2019)
- 06 Aug 2019 Launched for Benign prostatic hyperplasia in Myanmar (PO) (Kissei Pharmaceutical pipeline August 2019)